At a glance
- Originator Schering-Plough
- Class Antineoplastics
- Mechanism of Action Phospholipase D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jul 1998 Profile reviewed
- 13 Jul 1998 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 08 Dec 1994 Preclinical development for Cancer in USA (Unknown route)